IGC Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -711.67% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -116.24% beat CEL-SCI's return on equity of --.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1335.19%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3601.99%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

IGC Pharma has a beta of 1.449, which suggesting that the stock is 44.948% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are larger than CEL-SCI quarterly revenues of --. IGC Pharma's net income of -$1.8M is higher than CEL-SCI's net income of -$7.1M. Notably, IGC Pharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 15.88x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -711.67% compared to IGC Pharma's net margin of -49.65%. IGC Pharma's return on equity of -116.24% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1335.19%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 64.47%. Given that IGC Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGC Pharma is more attractive than NovaBay Pharmaceuticals.

IGC Pharma has a beta of 1.449, which suggesting that the stock is 44.948% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGC Pharma's net income of -$1.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IGC Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 15.88x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of 35.65%. IGC Pharma's return on equity of -116.24% beat Protalix BioTherapeutics's return on equity of 8.75%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1335.19%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 506.7%. Given that IGC Pharma has higher upside potential than Protalix BioTherapeutics, analysts believe IGC Pharma is more attractive than Protalix BioTherapeutics.

IGC Pharma has a beta of 1.449, which suggesting that the stock is 44.948% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. IGC Pharma's net income of -$1.8M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, IGC Pharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 79.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 15.88x versus 3.71x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -711.67% compared to IGC Pharma's net margin of -2357.27%. IGC Pharma's return on equity of -116.24% beat Palatin Technologies's return on equity of --.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1335.19%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that IGC Pharma has higher upside potential than Palatin Technologies, analysts believe IGC Pharma is more attractive than Palatin Technologies.

IGC Pharma has a beta of 1.449, which suggesting that the stock is 44.948% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Palatin Technologies quarterly revenues of $350K. IGC Pharma's net income of -$1.8M is higher than Palatin Technologies's net income of -$2.4M. Notably, IGC Pharma's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 15.88x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.